Zogenix Faces A Tough Biotech IPO Climate
This article was originally published in The Pink Sheet Daily
The San Diego biotech significantly lowered its IPO price to $4 per share as it entered an unwelcoming market.
You may also be interested in...
At least a dozen companies that roughly fit the description of a venture-backed, R&D focused biotech or small pharmaceutical company have gone public since mid-2009. Here we look at how valuations stack up compared to M&A and previous IPO windows.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.